Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Atle Fund Management AB

Q1 2024 · 13F-HR

Atle Fund Management ABholdings as filed

Filed 2024-04-25 · accession 0001381843-24-000004

$164.4M
Reported value
44
Positions
2024-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
58933Y105MRKMERCK & CO INC$17.6M10.7%133,741CommonSOLE
532457108LLYELI LILLY & CO$16.2M9.84%20,778CommonSOLE
91324P102UNHUNITEDHEALTH GROUP INC$11.4M6.94%23,041CommonSOLE
883556102TMOTHERMO FISHER SCIENTIFIC INC$8.8M5.37%15,186CommonSOLE
64125C109NBIXNEUROCRINE BIOSCIENCES INC$6.0M3.65%43,480CommonSOLE
413197104HRMYHARMONY BIOSCIENCES HLDGS IN$5.7M3.47%170,000CommonSOLE
863667101SYKSTRYKER CORPORATION$5.4M3.30%15,154CommonSOLE
031162100AMGNAMGEN INC$5.4M3.27%18,891CommonSOLE
00287Y109ABBVABBVIE INC$5.3M3.25%29,346CommonSOLE
101137107BSXBOSTON SCIENTIFIC CORP$5.3M3.23%77,401CommonSOLE
75886F107REGNREGENERON PHARMACEUTICALS$5.2M3.16%5,393CommonSOLE
03073E105CORCENCORA INC$5.0M3.02%20,426CommonSOLE
60855R100MOHMOLINA HEALTHCARE INC$4.9M3.00%12,000CommonSOLE
92532F100VRTXVERTEX PHARMACEUTICALS INC$4.7M2.87%11,295CommonSOLE
68404L201OPCHOPTION CARE HEALTH INC$4.5M2.71%132,895CommonSOLE
036752103ELVELEVANCE HEALTH INC$3.8M2.33%7,400CommonSOLE
375558103GILDGILEAD SCIENCES INC$3.8M2.32%52,000CommonSOLE
252131107DXCMDEXCOM INC$3.6M2.22%26,283CommonSOLE
604749101MIRMMIRUM PHARMACEUTICALS INC$3.1M1.88%123,000CommonSOLE
14149Y108CAHCARDINAL HEALTH INC$3.1M1.87%27,500CommonSOLE
03152W109AM6AMICUS THERAPEUTICS INC$3.0M1.81%252,307CommonSOLE
36118A100FUSION PHARMACEUTICALS INC$3.0M1.80%138,836CommonSOLE
462222100IONSIONIS PHARMACEUTICALS INC$2.8M1.68%63,791CommonSOLE
45258D105IMCRIMMUNOCORE HLDGS PLC$2.7M1.62%40,899CommonSOLE
46116X101ITCIEURINTRA-CELLULAR THERAPIES INC$2.6M1.60%38,050CommonSOLE
46266C105IQVIQVIA HLDGS INC$2.5M1.55%10,058CommonSOLE
28176E108EWEDWARDS LIFESCIENCES CORP$2.4M1.44%24,775CommonSOLE
82489T104SWAVUSDSHOCKWAVE MED INC$1.5M0.94%4,751CommonSOLE
21833P301CRBPCORBUS PHARMACEUTICALS HLDGS$1.5M0.91%38,000CommonSOLE
12674W109CABACABALETTA BIO INC$1.3M0.80%77,540CommonSOLE
03940C100ACLXGBXARCELLX INC$1.2M0.74%17,496CommonSOLE
501147102KRYSKRYSTAL BIOTECH INC$1.2M0.72%6,624CommonSOLE
10806X102BBIOBRIDGEBIO PHARMA INC$1.2M0.71%37,841CommonSOLE
30063P105EXKEXACT SCIENCES CORP$1.1M0.68%16,120CommonSOLE
N5749R1002GHMERUS N V$1.1M0.67%24,325CommonSOLE
457730109INSPINSPIRE MED SYS INC$1.0M0.62%4,782CommonSOLE
23282W605CYTKCYTOKINETICS INC$981,5400.60%14,000CommonSOLE
558868105MDGLMADRIGAL PHARMACEUTICALS INC$945,0550.58%3,539CommonSOLE
556099109MGNXMACROGENICS INC$725,7990.44%49,307CommonSOLE
00973Y108AKROAKERO THERAPEUTICS INC$617,1520.38%24,432CommonSOLE
05280R100AUTLAUTOLUS THERAPEUTICS PLC$614,6810.37%96,345CommonSOLE
N62509109NAMSNEWAMSTERDAM PHARMA COMPANY$529,6180.32%22,394CommonSOLE
61775R105MORFUSDMORPHIC HLDG INC$526,3100.32%14,952CommonSOLE
59045L106MERSANA THERAPEUTICS INC$448,0000.27%100,000CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.